Autoimmune Hemolytic Anemia Treatment Market To Reach $1.16 Billion By 2030

Autoimmune Hemolytic Anemia Treatment Market Growth & Trends

The global autoimmune hemolytic anemia treatment market is anticipated to reach USD 1.16 billion by 2030, growing at a CAGR of 6.5% from 2024 to 2030, according to a new report by Grand View Research, Inc. Increasing number of autoimmune hemolytic anemia (AIHA) cases worldwide, introduction of novel therapeutic drugs, increasing R&D activities, and favorable government initiatives are some of key factors driving the growth. For instance, the incidence of AIHA in France and Denmark is estimated at around 2.4 per 100,000 and 17.0 per 100,000 population, respectively.

Increasing research & activities to develop novel drugs for AIHA treatment is anticipated to drive the market expansion. Pharmaceutical companies and research institutes are actively involved in the development of novel and effective treatment options to manage AIHA. For instance, Zenas BioPharma is involved in the development of obexelimab for patients with warm autoimmune hemolytic anemia(wAIHA). The drug is in phase 3 of clinical trials and is being evaluated for efficacy and safety in patients with wAIHA. Similarly, Novartis AG is conducting clinical trials to evaluate the safety and efficacy of Ianalumab (VAY736) in patients who failed at least one line of treatment for warm autoimmune hemolytic anemia.

Moreover, the increasing involvement of government institutes and favorable initiatives undertaken by regulatory bodies to improve healthcare services to manage rare diseases are expected to increase the introduction of effective therapeutic solutions in the coming years. For instance, in December 2019, the U.S. FDA granted orphan drug designation to nipocalimab for the treatment of wAIHA and in July 2019, the U.S. FDA granted fast track designation for nipocalimab for the same indication. Such special designations for investigating candidates are expected to speed up the clinical trials and approval process.

Key players are adopting various market strategies such as acquisition and new product development to strengthen their market position. For instance, in September 2023, Bristol Myers Squibb acquired Asian regional market rights for bifunctional monoclonal antibody obexelimab from Zenas BioPharma, paying USD 50 million. Moreover, in June 2022, Rigel Pharmaceuticals, Inc. announced the results of phase 3 clinical trials of fostamatinib in patients with wAIHA, showing that patients treated with fostamatinib had a favorable durable hemoglobin response at the U.S., Canadian, Australian, and Western European trial sites.

 Request a free sample copy or view report summary: Autoimmune Hemolytic Anemia Treatment Market Report

Autoimmune Hemolytic Anemia Treatment Market Report Highlights

• The warm autoimmune hemolytic anemia type segment dominated the market in 2023 owing to a high prevalence of wAIHA and treatment rate.

• The corticosteroids segment held the largest market share in 2023, owing to the high prescription rate. Moreover, corticosteroids are considered as the first line of treatment for AIHA.

• The other drug class segment is projected to experience the fastest growth during the projected years owing to increasing R&D and approval of biological drugs.

• In the route of administration segment, oral drugs are anticipated to grow at the fastest rate owing to the increasing adoption of patient-centric approaches and the presence of promising oral drugs such as rilzabrutinib in the pipeline.

• North America dominated the market owing to factors such as high disease incidence, the presence of strong market players, and better reimbursement policies in the region.

Autoimmune Hemolytic Anemia Treatment Market Segmentation

Grand View Research has segmented the global autoimmune hemolytic anemia treatment market based on type, drug class, route of administration, distribution channel, and region:

Autoimmune Hemolytic Anemia Treatment Type Outlook (Revenue, USD Million, 2018 - 2030)

• Warm Autoimmune Hemolytic Anemia

• Cold Autoimmune Hemolytic Anemia

• Others

Autoimmune Hemolytic Anemia Treatment Drug Class Outlook (Revenue, USD Million, 2018 - 2030)

• Corticosteroids

• Immunosuppressive Agents

• Others

Autoimmune Hemolytic Anemia Treatment Route of Administration Outlook (Revenue, USD Million, 2018 - 2030)

• Injectable

• Oral

• Others

Autoimmune Hemolytic Anemia Treatment Distribution Channel Outlook (Revenue, USD Million, 2018 - 2030)

• Hospital Pharmacy

• Retail Pharmacy

• Online Pharmacy

Autoimmune Hemolytic Anemia Treatment Region Outlook (Revenue, USD Million, 2018 - 2030)

• North America

  • U.S.

  • Canada

• Europe

  • UK

  • Germany

  • France

  • Italy

  • Spain

  • Denmark

  • Sweden

  • Norway

• Asia Pacific

  • Japan

  • China

  • India

  • Thailand

  • South Korea

  • Australia

• Latin America

  • Brazil

  • Mexico

  • Argentina

• Middle East & Africa

  • South Africa

  • Saudi Arabia

  • UAE

  • Kuwait

List of Key Players in the Autoimmune Hemolytic Anemia Treatment Market

• F. Hoffmann-La Roche Ltd

• Viatris Inc.

• Teva Pharmaceutical Industries Ltd.

• Sanofi

• Lupin

• Johnson & Johnson Services, Inc.

• Novartis AG

• Incyte

• Rigel Pharmaceuticals, Inc.

• Alpine Immune Sciences